Core Viewpoint - The article discusses the tax deduction policies for advertising and business promotion expenses for enterprises, highlighting specific regulations and limits for different industries [6][9]. Group 1: Tax Deduction Regulations - Enterprises can deduct advertising and business promotion expenses up to 15% of their annual sales revenue, with any excess allowed to be carried forward to future tax years [6]. - For cosmetics, pharmaceuticals, and non-alcoholic beverage manufacturing and sales, the deductible limit is increased to 30% of annual sales revenue [9]. - Tobacco companies are prohibited from deducting any advertising and business promotion expenses when calculating taxable income [9]. Group 2: Related Policies and Timeframe - The current policies will remain effective from January 1, 2026, to December 31, 2027, allowing continued enjoyment of the specified tax benefits [8]. - Enterprises can share advertising and business promotion expenses through agreements, allowing one party to deduct expenses within the allowable limits while the other party can also benefit from the shared deductions [9]. Group 3: Legal Basis - The regulations are based on the "Implementation Regulations of the Corporate Income Tax Law of the People's Republic of China" and other relevant announcements from the Ministry of Finance and the State Administration of Taxation [11].

古汉医药公告，预计2025年度净利润亏损4500万元至5500万元。受行业政策等因素影响，加之上游部分 原材料采购成本上涨，致使整体毛利略有下降。 ...

Core Viewpoint - The company Nengte Technology has released its annual performance forecast, expecting a significant increase in net profit for 2025, driven primarily by the growth in its vitamin E business, despite challenges in its pharmaceutical intermediates segment and other non-recurring losses [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 200 million to 250 million yuan for 2025, representing a year-on-year increase of 134.01% to 142.51% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be around 320 million to 390 million yuan, reflecting a year-on-year increase of 162.06% to 175.63% [1] Group 2: Business Segments - The vitamin E business is expected to contribute no less than 660 million yuan to the company's profits, significantly boosting overall performance for 2025 [1] - The pharmaceutical intermediates segment, particularly the sales of Montelukast sodium intermediates, has underperformed due to delayed market demand and lower-than-expected sales [1] - The competition in the market for Rosuvastatin intermediates has intensified, leading to a decline in market prices and profits [1] Group 3: Non-Recurring Items - The company plans to recognize an impairment loss of no more than 260 million yuan related to goodwill due to the underperformance of the pharmaceutical intermediates [1] - The sale of a wholly-owned subsidiary, Shaanxi Ankang Shenqian Mining Co., Ltd., is expected to reduce profits by 48.87 million yuan, categorized as a non-recurring loss [1] - Legal proceedings are anticipated to result in a profit reduction of 79.59 million yuan for 2025, also classified as a non-recurring loss [1]

Group 1 - The core viewpoint of the news highlights significant projected profit increases for various companies in 2025, driven by rising production and sales in precious metals and advancements in technology sectors [1][3]. Group 2 - Xiaocheng Technology anticipates a net profit increase of 93%-179% year-on-year in 2025, with growth in gold production, sales, and international gold prices [1]. - Hunan Silver expects a net profit increase of 67.88%-126.78% in 2025, supported by rising silver and gold production and sales [3]. - Industrial Fulian projects a 56%-63% year-on-year increase in net profit for Q4 2025, with AI server revenue growth exceeding 50% quarter-on-quarter and over 5.5 times year-on-year [3]. - Keda Xunfei forecasts a net profit increase of 40%-70% in 2025, benefiting from the scaling of artificial intelligence applications [3]. - Albitex anticipates a net profit increase of 100.96% in 2025, primarily due to its focus on aerospace and expansion into the civilian market [3]. - Companies like Hainan Mining and Meixin Sheng are also making strategic acquisitions and investments to enhance their market positions [3].

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" introduces significant changes aimed at enhancing drug safety and innovation, with a focus on accelerating drug approval processes and establishing market exclusivity for pediatric and rare disease drugs [1][4][8]. Group 1: Regulatory Changes - The revised regulations represent the first comprehensive update in 23 years, with over 90% of the provisions modified, reflecting a shift towards stricter compliance and enforcement [1][2]. - The regulations elevate previously established policies on drug review and approval to legal requirements, indicating a higher level of compliance obligation for pharmaceutical companies [2]. Group 2: Innovation and R&D - The regulations explicitly support research and development (R&D) innovation, emphasizing clinical value as a core principle for drug development and encouraging the creation of new drugs [4][6]. - The introduction of four accelerated drug approval pathways aims to expedite the market entry of innovative drugs, with a notable reduction in average review times by 25% since 2018 [7][8]. Group 3: Market Dynamics - The regulatory changes are expected to drive a transformation in the pharmaceutical industry, pushing companies towards original innovation and global market competition, moving away from low-level fast-follow strategies [1][6]. - The introduction of market exclusivity periods for pediatric drugs (up to 2 years) and rare disease drugs (up to 7 years) is anticipated to enhance the attractiveness of these segments for pharmaceutical companies [8]. Group 4: Compliance and Responsibility - The regulations shift the focus from managing drug production companies to managing drug marketing authorization holders, thereby enforcing stricter accountability throughout the drug lifecycle [10][11]. - The new compliance framework necessitates that companies establish comprehensive quality assurance systems and adhere to stringent regulatory standards, which may increase operational costs, particularly for smaller firms [16][17]. Group 5: Quality Control and Enforcement - The regulations enhance quality supervision, particularly in online sales, and clarify the responsibilities of drug marketing authorization holders and third-party platforms [15][16]. - Stricter penalties for violations are introduced, including increased fines and enhanced criminal accountability, which are expected to raise compliance costs and pressure smaller companies [16][17].

Investment Rating - The report maintains a rating of "Outperform" for the company, indicating a positive outlook compared to the market [6]. Core Insights - The company's performance in 2025 is expected to meet forecasts, with a projected net profit of 60-66 million yuan, representing a year-on-year growth of 40.0-54.0% [6]. - Demand recovery is driving simultaneous growth in revenue and profit, particularly in various application fields such as culture media and nutritional products [6]. - Cost structure optimization is contributing positively to profit margins, with a reduction in certain expenses alleviating cost pressures [6]. - The company is set to release new production capacity and establish overseas subsidiaries to support market expansion [6]. - Long-term performance is expected to remain stable, with revenue forecasts for 2025-2027 at 404 million, 506 million, and 622 million yuan respectively, and corresponding net profits of 63 million, 83 million, and 108 million yuan [6]. Financial Data and Profit Forecast - Total revenue is projected to grow from 404 million yuan in 2025 to 622 million yuan in 2027, with a compound annual growth rate of approximately 22.9% [5]. - The net profit is expected to increase from 63 million yuan in 2025 to 108 million yuan in 2027, reflecting a strong growth trajectory [5]. - The company's gross margin is forecasted to remain stable around 31% to 32% over the next few years [5].

Market Overview - The market experienced fluctuations on January 28, with the Shanghai Composite Index rising by 0.27%, the Shenzhen Component Index increasing by 0.09%, and the ChiNext Index declining by 0.57% [2][12]. - A total of 1,739 stocks rose, 84 stocks hit the daily limit up, while 3,640 stocks fell [3][13]. Sector Performance - Resource stocks surged, with gold stocks leading the gains. Sichuan Gold achieved a four-day limit up, while Zhaojin Mining and Hunan Gold saw three consecutive limit ups [4][14]. - Oil and gas stocks collectively rose, with Tongyuan Petroleum and Zhongman Petroleum hitting the limit up, and China National Offshore Oil Corporation (CNOOC) increasing over 6% to reach a new high [5][16]. - The non-ferrous metals sector strengthened, with Silver Industry (Wei Quan) achieving seven consecutive limit ups, and China Aluminum hitting the limit up, marking a 16-year high [6][17]. - The coal sector also saw gains, with Shanxi Coking Coal and Shaanxi Black Cat hitting the limit up [7][18]. Declines - The pharmaceutical and medical stocks faced adjustments, with Bibete and Baipusais falling over 10% [8][19]. Trading Activity - Significant trading activity was noted, with the HuShen 300 ETF from Huatai-PB exceeding 30 billion yuan in trading volume, and other ETFs like the HuShen 300 ETF from E Fund and the CSI 500 ETF also surpassing 20 billion yuan [9][20]. - A report from CITIC Securities indicated that in previous bull markets, overheating trading conditions prompted cooling policies to prevent severe consequences, suggesting that the current proactive cooling measures are aimed at regulating market momentum without altering the overall positive policy stance [9][20].

Core Viewpoint - Fosun Pharma (600196.SH) announced the progress of guarantees provided for its subsidiaries, with total external guarantees amounting to approximately RMB 2,276,279 million, representing 48.16% of the audited net assets attributable to shareholders as of December 31, 2024 [1][2]. Group 1: Guarantee Details - As of January 27, 2026, the total amount of external guarantees, including the current guarantee, is approximately RMB 2,276,279 million [2]. - The company has no overdue guarantee matters as of January 27, 2026 [1]. - On January 26, 2026, the company entered into a guarantee contract with Bank of Communications, agreeing to provide a maximum joint liability guarantee for its subsidiary Fosun Pharma Industry for a financing contract not exceeding RMB 112,900 million [3]. Group 2: Credit Facilities and Agreements - On September 11, 2025, Fosun Yalifeng, a subsidiary, signed a credit agreement with China Merchants Bank for a credit limit of RMB 4,500 million, which was later increased to RMB 10,000 million [3]. - On January 26, 2026, Fosun Health signed a working capital loan agreement with Bank of Communications for a loan limit of RMB 5,000 million [4]. - Fosun Health also entered into factoring agreements with Agricultural Bank and Dalian Bank for financing limits of RMB 3,000 million and RMB 10,000 million, respectively [5][6]. Group 3: Additional Guarantees - On January 27, 2026, subsidiary Suzhou Erye signed a guarantee contract with Bank of Communications for a financing contract not exceeding RMB 6,000 million [6]. - On the same day, Beijing Beiling applied for a loan of RMB 1,500 million from Beijing Rural Commercial Bank, with Fosun Beiling providing a joint liability guarantee [7].

Group 1: Market Overview - The Hang Seng Index closed at 27,127, up 1.35% for the day and 5.84% year-to-date [1] - The Hang Seng Financial Index rose by 2.51% for the day and 5.88% year-to-date, indicating strong performance in the financial sector [2] - Southbound capital recorded a net sell of 635 million HKD, with notable sell-offs in China Mobile, Zijin Mining, and SMIC, while Tencent and Longi Green Energy saw significant net buying [3] Group 2: Company Analysis - Sanofi - Sanofi's collaboration with Pfizer on the 707/PF'4404 (PD-1/VEGF) has advanced rapidly, with plans to initiate four global Phase III clinical trials by 2026 covering five major indications [4] - The dual antibody PD-(L)1/VEGF is expected to become a cornerstone in next-generation tumor immunotherapy, with Sanofi leveraging its internal pipeline for competitive advantage [5] - Sanofi's robust pipeline includes multiple candidates, with the potential for early assets to be licensed out as clinical data matures [6] Group 3: Financial Projections - The target price for Sanofi is set at 37.43 HKD, based on a DCF model with a WACC of 10.11% and a perpetual growth rate of 2.0% [7] - The company is estimated to have net cash of approximately 13 billion HKD, supporting its growth and development initiatives [7]

Economic Performance - Dalian's GDP reached 1000.21 billion yuan in 2025, with a year-on-year growth of 5.7%, indicating a significant milestone in the city's high-quality development [1] - The quarterly GDP growth rates were 6.2%, 6%, 6%, and 5.7%, surpassing the national average and exceeding expectations [1] Industrial Growth - The added value of key industries such as railway, shipbuilding, pharmaceuticals, and automotive manufacturing grew by 57.5%, 30.9%, and 19.5% respectively, with high-tech manufacturing increasing by 13.9% [1] - Major projects like the electric vehicle battery project and wind power, hydrogen energy industrial parks are under rapid development, contributing to the new energy sector [1] Project Development - Dalian secured 36.86 billion yuan in central project funding, a 50.1% increase, and initiated 1,369 projects worth over 100 million yuan, a growth of 14.1% [2] - Key projects such as the international airport and cross-sea bridge are accelerating construction, while major projects like the nuclear power plant are advancing [2] Technological Advancements - The city is focusing on high-end technology, achieving significant domestic production in critical components like wind turbine gearboxes and delivering large-scale vessels [3] - Dalian established 5 national-level smart factories and 74 advanced smart factories, enhancing its industrial internet capabilities [3] Green Development - The city added 23 provincial-level green factories and 9 green supply chain management enterprises, showcasing significant progress in green development [3] - Dalian aims to achieve a clean energy generation capacity ratio of 64% and a generation volume ratio of 75% [1]